Dublin, Feb. 13, 2020 (GLOBE NEWSWIRE) -- The "Major Depressive Disorder (MDD) - Epidemiology Forecast - 2028" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of MDD in the 7 Major Markets (MM) i.e., United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The report includes details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines. A major depressive disorder is the most prevalent and disabling form of depression. In addition to the immediate symptoms of depression, MDD results in the poor quality of life overall decreased productivity and affect females more than males. MDD is one form of depressive illness or mood disorder. Other forms include bipolar disorder (manic-depressive illness) and dysthymia.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (12 months prevalent cases of Major Depressive Disorder, age-specific cases of Major Depressive Disorder, gender-specific cases of Major Depressive Disorder, severity-specific cases of Major Depressive Disorder, treatable cases of Major Depressive Disorder, relapsed/refractory cases of Major Depressive Disorder) scenario of MDD from 2017-2028.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight. A total of 12 months prevalent population of Major Depressive Disorder in 7 major markets was observed to be 34,011,712 cases in 2017.
Report Scope
- The report covers the descriptive overview of Major Depressive Disorder, explaining its causes and currently available therapies
- Comprehensive insight has been provided into the epidemiology of the Major Depressive Disorder and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan
- Additionally, an all-inclusive account of both the current and emerging therapies for Major Depressive Disorder are provided, along with assessment of the impact new therapies will have on the current treatment landscape
- A detailed review of global historical and forecasted Major Depressive Disorder market is included in the report, covering drug outreach in 7 MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Major Depressive Disorder market
Major Depressive Disorder Report Key Strengths
- 9 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Key Cross Competition
- Market Size by Therapies
- Drugs Uptake
Major Depressive Disorder Epidemiology Segmentation
- 12 months of prevalent cases of Major Depressive Disorder
- Age-specific cases of Major Depressive Disorder in 7 MM
- Gender-specific cases of Major Depressive Disorder, in 7 MM
- Severity-specific cases of Major Depressive Disorder in 7 MM
- Treatable cases of Major Depressive in 7 MM
- Relapsed/refractory cases of Major Depressive Disorder in 7 MM
Key Topics Covered:
1. Key Insights
2. Disease Overview: Major Depressive Disorder (MDD)
2.1. Introduction
2.2. Sign and Symptoms
2.3. Types of Major Depressive Disorder
2.4. Causes of Major Depressive Disorder
2.5. Pathophysiology of Depression
2.6. Genetic Basis of Major Depressive Disorder
2.7. Biomarkers in MDD
2.8. Diagnosis and Severity
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. 7MM Total 12 Months Prevalent Patient Population of Major Depressive Disorder
4. Country Wise-Epidemiology of Major Depressive Disorder
5. Current Treatment Practices
5.1. American Psychiatric Association: Guideline on the Treatment of Patients with Major Depressive Disorder
5.2. Major Depressive Disorder Treatment Guidelines in the US and Europe
5.3. Guidelines in Spanish SHN for the Management of Major Depression in Adults
5.4. Major Depressive Disorder Treatment Guidelines in Japan
5.5. Major depressive disorder -Clinical practice review
5.6. Algorithm for the Management of Major Depressive Disorder
5.7. Algorithm for the Pharmacotherapy of MDD
6. Appendix
6.1. Report Methodology
7. Capabilities
For more information about this report visit https://www.researchandmarkets.com/r/3x3sm6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.